Phase i dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Immunoconjugates
  • Kidney Neoplasms
  • Lymphoma, Non-Hodgkin
  • Neoplasm Recurrence, Local
  • Oligopeptides

abstract

  • Modest single-agent activity and generally manageable adverse events were observed in heavily pretreated RCC and NHL patients. Administration Q3Wk was better tolerated than weekly dosing. Targeted ablation of CD70-positive lymphocytes was demonstrated.

publication date

  • December 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s10637-014-0151-0

PubMed ID

  • 25142258

Additional Document Info

start page

  • 1246

end page

  • 57

volume

  • 32

number

  • 6